Room-temperature X-ray powder diffraction data for bosentan monohydrate
Source abstract
Abstract
Abstract The room-temperature X-ray powder diffraction data for bosentan monohydrate, an API used in the treatment of pulmonary arterial hypertension, is presented. Bosentan monohydrate is monoclinic, P 2 1 / c (No. 14), with unit cell parameters a = 12.4520(7) Å, b = 15.110(1) Å, c = 15.0849(9) Å, β = 95.119(5)°, V = 2827.0(3) Å 3 , Z = 4. All the diffraction maxima recorded were indexed and are consistent with the P 2 1 / c space group. The crystal structure of this material corresponds to the phase associated with Cambridge Structural Database entry NEQHEY, which was determined at 123 K. The successful Rietveld refinement, carried out with TOPAS-Academic, showed the single-phase nature of the material and the good quality of the data. A comprehensive analysis of intra- and intermolecular interactions corroborates that the structure is dominated by extensive hydrogen bonding, accompanied by C▬H⋯π and π⋯π interactions. Hirshfeld surface analysis and fingerprint plots indicate that the most important interactions are H⋯H and O⋯H/H⋯O in bosentan and the water molecule and C⋯H/H⋯C interactions in bosentan.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: X-ray Diffraction in Crystallography · Crystallography and molecular interactions · Thermal and Kinetic Analysis
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
References (45)
Show source-provided references
1. ICDD. 2022. JADE® Pattern Digitizer. https://www.icdd.com/jade-pattern-digitizer/?page=www.icdd.com/JadeSAS/jade-pattern-digitizer/. Accessed May 4, 2024.
2. 10.1107/S160057671700114510.1107/S1600576717001145 ↗
3. 10.1107/S160053681204896910.1107/S1600536812048969 ↗
4. 10.1016/j.ijpharm.2022.12184610.1016/j.ijpharm.2022.121846 ↗
5. 10.1017/S088571561900051410.1017/S0885715619000514 ↗
6. 10.1107/S205698902101363310.1107/S2056989021013633 ↗
7. 10.1107/S160057671800018310.1107/S1600576718000183 ↗
8. 10.3390/jcm903082410.3390/jcm9030824 ↗
9. 10.1016/j.molliq.2017.03.04610.1016/j.molliq.2017.03.046 ↗
10. 10.1107/S002188987901178X10.1107/S002188987901178X ↗
11. 10.1017/S088571562200038010.1017/S0885715622000380 ↗
12. Cotarca, L. , Verzini, M. , Melotto, E. , Michieletto, I. , Melloni, A. , Maragni, P. , Volpicelli, R. , Andretto, M. , and Colli, C. . 2011. “Verfahren zur Herstellung von Bosetanmonohydrat und Zwischenprodukten Davon.” Patent Assignee Zach System SpA, Application No. 11761348.9, Patent EP2621909B1, 22 September 2011. https://patents.google.com/patent/EP2621909B1/de.
13. 10.1517/1465656100369185410.1517/14656561003691854 ↗
14. 10.1107/S002188986800508X10.1107/S002188986800508X ↗
15. 10.2147/DDDT.S12035610.2147/DDDT.S120356 ↗
16. 10.1107/S002188981301877310.1107/S0021889813018773 ↗
17. Putz, H. and Brandenburg, K. . 2023. Diamond-Crystal and Molecular Structure Visualization, Crystal Impact-GbR, Kreuzherrenstr, Bonn, Germany 102: 53227, https://www.crystalimpact.de/diamond.
18. 10.1107/S205698901600907510.1107/S2056989016009075 ↗
19. 10.1107/S002188981202115210.1107/S0021889812021152 ↗
20. 10.1017/S088571562400015010.1017/S0885715624000150 ↗
21. 10.1017/S088571561400090610.1017/S0885715614000906 ↗
22. Analiza Wodzianów Substancji Czynnych. (Analysis of Pharmaceutical Hydrates)
23. 10.1107/S205252062300775810.1107/S2052520623007758 ↗
24. 10.1107/S205698901901624410.1107/S2056989019016244 ↗
25. 10.1021/acs.cgd.0c0028410.1021/acs.cgd.0c00284 ↗
26. 10.1039/B818330A10.1039/B818330A ↗
27. Sidoryk, K. , Łuniewski, W. , Puchalska, M. , Łaszcz, M. , Maruszak, W. , and Kościuch, M. . 2014. “Process for Preparation of Bosentan Monohydrate of Pharmaceutical Purity.” Patent Assignee Instytut Farmaceutyczny, Application No. PCT/PL2013/000173, Patent WO2014104904A1, 3 July 2014. https://patents.google.com/patent/WO2014104904A1/ru.
28. 10.1107/S160057672100291010.1107/S1600576721002910 ↗
29. Mathad, V. T. , Niphade, N. C. , Jagtap, K. M. , and Gaikwad, C. T. , 2011. “Process for Preparation of Bosentan.” Patent Assignee Megafine Pharma P Ltd, Application No. 13/816,376, Patent US9139537B2, 28 March 2011. https://patents.google.com/patent/US9139537B2/en.
30. 10.1016/0025-5408(88)90019-010.1016/0025-5408(88)90019-0 ↗
31. 10.1021/acs.molpharmaceut.1c0061310.1021/acs.molpharmaceut.1c00613 ↗
32. 10.1107/S002188988100961810.1107/S0021889881009618 ↗
33. 10.1107/S160057671901409210.1107/S1600576719014092 ↗
34. 10.1021/ci049780b10.1021/ci049780b ↗
35. Trzcińska · 2016
36. 10.1107/S205252061600395410.1107/S2052520616003954 ↗
37. Teksi̇n, Z. Ş. , and Usta, D. Yilmaz . 2020. “Bosentan Monohydrate Loaded Liquid Self Nanoemulsifying Drug Carrier System and Tablet Formulation.” Patent Assignee Teksi̇n, Z. Ş. and Yilmaz Usta, D. Application No. PCT/TR2020/050945, Patent WO2021076081A2, 13 October 2020. https://patents.google.com/patent/WO2021076081A3/en.
38. Andretto, M. , Colli, C. , Cotarca, L. , Maragni, P. , Melloni, A. , Melotto, E. , Michieletto, I. , Verzini, M. , and Volpicelli, R. . 2011. “Process for Preparing Bosentan Monohydrate and its Intermediates.” Patent Assignee Zach System SpA, Application No. 2011310754, Patent AU2011310754B2, 22 September 2011. https://patents.google.com/patent/AU2011310754B2/en.
39. 10.1016/j.bfopcu.2016.12.00410.1016/j.bfopcu.2016.12.004 ↗
40. A Probabilistic Approach to Space-Group Determination from Powder Diffraction Data
41. 10.1039/C5RA18618H10.1039/C5RA18618H ↗
42. 10.1039/D2CE00581F10.1039/D2CE00581F ↗
43. Formulation and Characterization of Polymeric Nanoparticle of Antihypertensive Drug Bosentan
44. 10.1002/btpr.274810.1002/btpr.2748 ↗
45. Rodriguez-Carvajal, J. 1990. “FULLPROF: a Program for Rietveld Refinement and Pattern Matching Analysis.” Abstracts of the Satellite Meeting on Powder Diffraction of the XV Congress of the IUCr, Toulouse, France, p. 127.